RU2014121390A - Новые дизамещенные соединения 3,4-диамино-3-циклобутен-1,2-диона для использования при лечении опосредованных цитокинами заболеваний - Google Patents
Новые дизамещенные соединения 3,4-диамино-3-циклобутен-1,2-диона для использования при лечении опосредованных цитокинами заболеваний Download PDFInfo
- Publication number
- RU2014121390A RU2014121390A RU2014121390/04A RU2014121390A RU2014121390A RU 2014121390 A RU2014121390 A RU 2014121390A RU 2014121390/04 A RU2014121390/04 A RU 2014121390/04A RU 2014121390 A RU2014121390 A RU 2014121390A RU 2014121390 A RU2014121390 A RU 2014121390A
- Authority
- RU
- Russia
- Prior art keywords
- group
- methyl
- atom
- hydrogen atom
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552940P | 2011-10-28 | 2011-10-28 | |
| US61/552,940 | 2011-10-28 | ||
| FR1159833 | 2011-10-28 | ||
| FR1159833A FR2981935B1 (fr) | 2011-10-28 | 2011-10-28 | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| PCT/FR2012/052478 WO2013061004A1 (fr) | 2011-10-28 | 2012-10-26 | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014121390A true RU2014121390A (ru) | 2015-12-10 |
Family
ID=45809111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014121390/04A RU2014121390A (ru) | 2011-10-28 | 2012-10-26 | Новые дизамещенные соединения 3,4-диамино-3-циклобутен-1,2-диона для использования при лечении опосредованных цитокинами заболеваний |
Country Status (24)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105960237B (zh) | 2013-12-02 | 2020-03-31 | 凯莫森特里克斯股份有限公司 | Ccr6化合物 |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| WO2019036374A1 (en) | 2017-08-14 | 2019-02-21 | Allergan, Inc. | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND THEIR USE |
| CN111867579B (zh) | 2018-01-08 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| IL281634B2 (en) | 2018-09-21 | 2025-02-01 | Pfizer | Modified diisocyclobutenylamino-3-hydroxy-picolinamide and its use as a CCR6 inhibitor |
| JP7789693B2 (ja) | 2020-04-30 | 2025-12-22 | イドルシア・ファーマシューティカルズ・リミテッド | Ｃｃｒ６受容体調節剤としてのアゼチジン－３－イルメタノール誘導体 |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| JP2024539987A (ja) | 2021-10-26 | 2024-10-31 | イドルシア・ファーマシューティカルズ・リミテッド | Ｃｃｒ６受容体調節剤 |
| MX2024005123A (es) | 2021-10-28 | 2024-05-16 | Idorsia Pharmaceuticals Ltd | Moduladores del receptor ccr6. |
| CN121079289A (zh) * | 2023-04-28 | 2025-12-05 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
| WO2025092968A1 (zh) * | 2023-11-03 | 2025-05-08 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652737B2 (en) * | 2000-07-21 | 2003-11-25 | Exxonmobil Research And Engineering Company | Production of naphtha and light olefins |
| MXPA03009441A (es) * | 2001-04-16 | 2004-02-12 | Schering Corp | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc. |
| WO2008148790A1 (en) * | 2007-06-06 | 2008-12-11 | Novartis Ag | Anti -inflammatory substituted cyclobutenedione compounds |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| KR200444641Y1 (ko) * | 2008-12-03 | 2009-05-27 | 강민수 | 헤드작동형 다기능 스패너 |
| WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
-
2011
- 2011-10-28 FR FR1159833A patent/FR2981935B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-26 PL PL12791825.8T patent/PL2771329T3/pl unknown
- 2012-10-26 CN CN201280052911.8A patent/CN103906738B/zh not_active Expired - Fee Related
- 2012-10-26 WO PCT/FR2012/052478 patent/WO2013061004A1/fr not_active Ceased
- 2012-10-26 IN IN2273CHN2014 patent/IN2014CN02273A/en unknown
- 2012-10-26 RU RU2014121390/04A patent/RU2014121390A/ru not_active Application Discontinuation
- 2012-10-26 BR BR112014009889A patent/BR112014009889A2/pt not_active IP Right Cessation
- 2012-10-26 HR HRP20160608TT patent/HRP20160608T1/hr unknown
- 2012-10-26 JP JP2014537704A patent/JP6068486B2/ja not_active Expired - Fee Related
- 2012-10-26 AU AU2012328198A patent/AU2012328198A1/en not_active Abandoned
- 2012-10-26 US US14/354,033 patent/US9388149B2/en not_active Expired - Fee Related
- 2012-10-26 DK DK12791825.8T patent/DK2771329T3/en active
- 2012-10-26 SI SI201230577A patent/SI2771329T1/sl unknown
- 2012-10-26 ES ES12791825.8T patent/ES2569053T3/es active Active
- 2012-10-26 RS RS20160367A patent/RS54775B1/sr unknown
- 2012-10-26 KR KR1020147011443A patent/KR20140090168A/ko not_active Withdrawn
- 2012-10-26 PT PT127918258T patent/PT2771329E/pt unknown
- 2012-10-26 CA CA2848263A patent/CA2848263A1/fr not_active Abandoned
- 2012-10-26 MX MX2014003958A patent/MX342924B/es active IP Right Grant
- 2012-10-26 EP EP12791825.8A patent/EP2771329B1/fr active Active
- 2012-10-26 HU HUE12791825A patent/HUE029128T2/en unknown
-
2014
- 2014-03-06 ZA ZA2014/01678A patent/ZA201401678B/en unknown
-
2016
- 2016-05-31 SM SM201600151T patent/SMT201600151B/it unknown
- 2016-06-02 CY CY20161100489T patent/CY1117705T1/el unknown
- 2016-06-07 US US15/175,363 patent/US9580412B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9388149B2 (en) | 2016-07-12 |
| SI2771329T1 (sl) | 2016-07-29 |
| CY1117705T1 (el) | 2017-05-17 |
| MX342924B (es) | 2016-10-19 |
| US20140296254A1 (en) | 2014-10-02 |
| PL2771329T3 (pl) | 2016-09-30 |
| AU2012328198A1 (en) | 2014-04-03 |
| DK2771329T3 (en) | 2016-06-06 |
| FR2981935A1 (fr) | 2013-05-03 |
| JP6068486B2 (ja) | 2017-01-25 |
| BR112014009889A2 (pt) | 2017-04-25 |
| EP2771329A1 (fr) | 2014-09-03 |
| JP2014530894A (ja) | 2014-11-20 |
| CA2848263A1 (fr) | 2013-05-02 |
| RS54775B1 (sr) | 2016-10-31 |
| IN2014CN02273A (cg-RX-API-DMAC7.html) | 2015-06-19 |
| EP2771329B1 (fr) | 2016-03-16 |
| WO2013061004A1 (fr) | 2013-05-02 |
| CN103906738A (zh) | 2014-07-02 |
| FR2981935B1 (fr) | 2015-08-07 |
| HRP20160608T1 (hr) | 2016-07-01 |
| ES2569053T3 (es) | 2016-05-06 |
| MX2014003958A (es) | 2014-08-27 |
| PT2771329E (pt) | 2016-06-17 |
| US20160362403A1 (en) | 2016-12-15 |
| CN103906738B (zh) | 2016-09-07 |
| KR20140090168A (ko) | 2014-07-16 |
| HUE029128T2 (en) | 2017-02-28 |
| SMT201600151B (it) | 2016-07-01 |
| ZA201401678B (en) | 2015-04-29 |
| US9580412B2 (en) | 2017-02-28 |
| WO2013061004A8 (fr) | 2014-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014121390A (ru) | Новые дизамещенные соединения 3,4-диамино-3-циклобутен-1,2-диона для использования при лечении опосредованных цитокинами заболеваний | |
| RU2014121394A (ru) | Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами | |
| RU2012141536A (ru) | Имидазопиридины, композиции и способы применения | |
| JP6203820B2 (ja) | １５−ｐｇｄｈ活性を調節する組成物および方法 | |
| AR073548A1 (es) | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| RU2011147200A (ru) | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы | |
| RU2012132426A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ | |
| RU2015143000A (ru) | N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств | |
| EP3877376A1 (en) | Pyridazinone compounds and uses thereof | |
| RU2004103741A (ru) | Новые соединения в качестве противовоспалительных, иммуномодулирующих и противопролиферативных агентов | |
| JP2014506599A5 (cg-RX-API-DMAC7.html) | ||
| WO2020097258A1 (en) | Pyridazinone compounds and uses thereof | |
| JP2013523652A5 (cg-RX-API-DMAC7.html) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| RU2016114866A (ru) | Замещенные аминопиримидиновые соединения и способы их использования | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2011046700A5 (cg-RX-API-DMAC7.html) | ||
| JP2015506355A5 (cg-RX-API-DMAC7.html) | ||
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| NO20091681L (no) | Modulatorer av glukortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og anvendelse derav | |
| JP2016501185A5 (cg-RX-API-DMAC7.html) | ||
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| JP2014524441A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170717 |